Emicizumab (Hemlibra®), By connecting FIXa and FX, In hemophilia A patients, a recombinant, humanized, Absent activated factor VIII (FVIII) is successfully functionally restored by a bispecific monoclonal antibody. Subcutaneous emicizumab has been approved in a number of countries for the routine prevention of bleeding episodes in patients with moderate to severe hemophilia A, with or without the use of FVIII inhibitors. In phase III clinical investigations, emicizumab prophylaxis significantly decreased annualized bleeding rates in adults and adolescents with hemophilia A with or without inhibitors and avoided or significantly reduced bleeding in children with hemophilia A with or without inhibitors. Regular use of emicizumab improved health-related quality of life with no discomfort. Emicizumab, regardless of the presence or absence of inhibitors, provides a consistent and frequently well-tolerated alternative to conventional FVIII replacement medications for the prevention of bleeding episodes in people with hemophilia A. This is because of the delivery method's practicality and the flexible dosage schedules (maintenance doses every 1, 2, or 4 weeks).